银翘散联合头孢哌酮/舒巴坦治疗社区获得性肺炎的疗效与安全性评估

目的:研究银翘散联合头孢哌酮/舒巴坦联合治疗社区获得性肺炎(community-acquirted pneumonia,CAP)的疗效与安全性。方法:选择120例社区获得性肺炎作为研究对象,随机分为两组,每组60例。对照组给予注射用头孢哌酮钠/舒巴坦钠治疗,观察组在对照组治疗的基础上采用银翘散治疗。观察两组患者临床疗效、肺部感染评分、药物浓度达到峰值的时间(Tmax)、达到峰值的浓度(Cmax)以及药物的半衰期(t1/2)及不良反应情况。结果:观察组治疗有效率高达98.3%,显著高于对照组治疗有效率80.0%,差异具有显著统计学意义(P0.05)。观察组临床肺部感染评分(CPIS)于治疗后5 d起明显低于治疗前、早于对照组;药物浓度峰值Cmax与对照组无差异。观察组达到峰值的时间Tmax、半衰期t1/2时间显著短于对照组,差异具有显著统计学意义(P0.05)。观察组总体生活质量高达(81.84±8.34)分,显著高于对照组(69.42±6.14)分,差异具有显著统计学意义(P0.05)。观察组发生头晕头痛、恶心呕吐、腹部不适、皮疹、肝功能损害及肾功能损害等不良反应例数均显著少于对照组,差异均具有显著统计学意义(P0.05)。结论:银翘散联合头孢哌酮/舒巴坦治疗代谢快、疗效好、不良反应少,具有积极的临床价值。

Efficacy and Safety Yinqiao San Combined with Cefoperazone/Sulbactam in Treating CAP

Objective: To study the efficacy and safety Yinqiao San combined with cefoperazone/sulbactam in treating community-acquired pneumonia(CAP). Method: CAP were collected as the research object and randomly divided into observation group given Yinqiao San and cefoperazone/sulbactam and control group given cefoperazone/sulbactam. Then recovery, metabolism of drugs and adverse reaction were observed. Result: Clinical pulmoncoy infection score(CPIS) score of observation group after treatment was obviously lower than before treatment from 5 d which was earlier than control group; drug concentration peak C_max had no difference with control group, time to peak T_max, t_1/2 and adverse reaction cases were significantly less than control group. Conclusion: Yinqiao San combined with cefoperazone/sulbactam have positive clinical value for its fast metabolic, good curative effect and less adverse reaction.